10-K: PDS Biotech Reports 2024 Results, Highlights Progress in Immunotherapy Pipeline

Sentiment:

Annual Results 27 March 2025 4:31 PM

PDS Biotechnology Corporation files its 10-K report for the year ended December 31, 2024, detailing its financial results and progress in developing its Versamune and Infectimune immunotherapy platforms.

Capital raiseThe company is pursuing additional funding through collaborations, strategic alliances, and potential equity or debt financings.In February 2025, the Company entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell an aggregate of 6,396,787 shares of common stock, pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant.

Worse than expectedThe company has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.The company acknowledges that there is substantial doubt about its ability to continue as a going concern within one year.

Summary

PDS Biotechnology Corporation is a clinical-stage immunotherapy company focused on developing targeted cancer immunotherapies and vaccines for infectious diseases.
The company's lead product candidates are based on its Versamune and Infectimune platforms, which aim to activate T cells to fight cancer and infectious agents.
PDS Biotech is also developing PDS01ADC, a tumor-targeting IL-12 fusion protein designed to enhance T cell activity in the tumor microenvironment.
Key clinical trials are ongoing, including VERSATILE-002 (Versamune HPV + Keytruda) for head and neck cancer and studies led by the National Cancer Institute (NCI) involving Versamune HPV and PDS01ADC.
The company has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.
As of December 31, 2024, PDS Biotech had $41.7 million in cash and cash equivalents.
The company is pursuing additional funding through collaborations, strategic alliances, and potential equity or debt financings.
PDS Biotech acknowledges that there is substantial doubt about its ability to continue as a going concern within one year.
The company is subject to extensive government regulations and faces intense competition in the biotechnology and pharmaceutical industries.
PDS Biotech relies on third-party manufacturers and CROs for clinical trials and manufacturing, which poses risks to its development programs.
The company is working to protect its intellectual property through patents and trade secrets.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there's promising clinical data and strategic partnerships, the company's financial situation and going concern warning temper the overall outlook.

Positives

PDS Biotech is developing innovative immunotherapy platforms with the potential to address unmet medical needs in cancer and infectious diseases.
The company has promising clinical data for Versamune HPV and PDS01ADC in various cancer types.
PDS Biotech has an exclusive global license agreement with Merck KGaA for PDS01ADC.
The company is pursuing a registrational study for Versamune HPV + pembrolizumab in head and neck cancer.
PDS Biotech has a strong intellectual property position with numerous patents and patent applications.

Negatives

PDS Biotech has incurred significant losses since its inception and expects to continue to incur losses for the foreseeable future.
The company has a limited operating history and has never generated any product revenue.
PDS Biotech is dependent on the success of its Versamune and Infectimune products, which are still in clinical development.
The company acknowledges that there is substantial doubt about its ability to continue as a going concern within one year.
PDS Biotech relies on third-party manufacturers and CROs for clinical trials and manufacturing, which poses risks to its development programs.

Risks

The company's ability to continue as a going concern is dependent on obtaining additional financing.
Clinical trials are expensive, time-consuming, and involve an uncertain outcome.
Enrollment and retention of subjects in clinical trials is a challenging process.
PDS Biotech faces significant competition from other biotechnology and biopharmaceutical companies.
The company relies on third parties to conduct clinical trials and perform research and preclinical studies.
PDS Biotech may expend its limited resources to pursue a particular product candidate or indication and fail to capitalize on other opportunities.
The company may be subject to product liability lawsuits.
PDS Biotech may be unable to obtain and/or maintain patent protection for its product candidates.
The company's stock price is expected to be volatile.
The company's effective tax rate may increase in the future.

Future Outlook

The company expects research and development expenses to increase significantly over the next several years as it advances its product candidates into and through clinical trials, pursues regulatory approval, and prepares for a possible commercial launch.

Industry Context

The biotechnology and pharmaceutical industries are characterized by intense competition to develop new technologies and proprietary products. PDS Biotech is competing with various established companies and development-stage biotechnology companies in the immunotherapy and vaccine development space.

Comparison to Industry Standards

The median overall survival of approximately 20 months in ICI-resistant patients treated with Versamune HPV and PDS01ADC compares favorably to the historical median survival of 3-4 months reported in ICI-resistant HPV-positive cancers when treated with ICIs and the best reported median survival to date with systemic therapy of 8.2 months in ICI-resistant head and neck cancer.
The 30-month median overall survival in ICI-nave patients with CPS > 1 in the VERSATILE-002 Phase 2 clinical trial compares favorably to published results for ICIs of 7-18 months.
The confirmed overall response rate of 34% in ICI-nave patients with CPS > 1 in the VERSATILE-002 Phase 2 clinical trial compares favorably to published results for comparable patients receiving treatment with ICIs of less than 20%.

Stakeholder Impact

Shareholders may experience dilution from future equity offerings.
Employees face uncertainty due to the company's financial situation.
Patients may benefit from the development of new immunotherapies.
Suppliers and creditors face risks related to the company's ability to continue as a going concern.

Next Steps

Continue clinical development of Versamune HPV, PDS01ADC, and other product candidates.
Pursue regulatory approval for Versamune HPV and other product candidates.
Initiate a registrational study in first-line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune HPV + pembrolizumab.
Seek additional funding through collaborations, strategic alliances, and potential equity or debt financings.

Key Dates

Date	Description
November 23, 2018	Agreement and Plan of Merger and Reorganization between Edge Therapeutics, Echos Merger Sub, Inc. and PDS Biotechnology Corporation.
January 24, 2019	Amendment No. 1 to Agreement and Plan of Merger and Reorganization.
March 15, 2019	Reverse merger completed, company name changed to PDS Biotechnology Corporation.
June 2020	First patient dosed in NCI-led Phase 2 trial evaluating Versamune HPV with PDS01ADC and Bintrafusp Alfa.
November 2020	VERSATILE-002 Phase 2 clinical trial commenced.
December 30, 2022	Exclusive global license agreement with Merck KGaA for PDS01ADC.
February 2023	Completion of Type B meeting with the FDA for Versamune HPV, PDS01ADC, and an FDA-approved immune checkpoint inhibitor.
May 2023	Completed enrollment in the ICI nave arm of VERSATILE-002.
June 2023	Abstract presented at ASCO 2023 on VERSATILE-002 study.
September 2023	Data on PDS0202 presented at the 9th European Scientific Working Group on Influenza (ESWI) conference.
October 2023	Data on Versamune HPV with chemoradiotherapy presented at the American Society for Radiation Oncology Annual Meeting.
October 2023	Updated interim data from VERSATILE-002 presented at a key opinion leader roundtable.
October 2023	Interim safety and immune response data for PDS01ADC in combination with docetaxel presented at the 11th Annual Meeting of the International Cytokine & Interferon Society.
October 2023	Immune response data from VERSATILE-002 presented at the European Society for Medical Oncology Congress 2023.
November 2023	Updated survival data from NCI-led Phase 2 trial released.
November 2023	Preclinical data from NCI-led trial presented at the Society for Immunotherapy of Cancer 38th Annual Meeting.
May 2024	Updated interim data from VERSATILE-002 presented at a virtual key opinion leader event.
June 2024	Data update from VERSATILE-002 clinical trial provided.
August 2024	Update to clinical strategy following discussions with the FDA, intent to initiate a registrational trial in first line treatment in HPV16-positive recurrent/metastatic HNSCC with the double combination of Versamune HPV + pembrolizumab.
September 2024	Updated data from VERSATILE-002 presented at the European Society for Medical Oncology (ESMO) Congress 2024.
October 2024	Updated data from IMMUNOCERV presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2024.
January 2025	Submitted an investigational new drug application to the FDA for a Phase 1 trial with PDS0103 and PDS01ADC in colorectal cancer.
February 2025	Entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell an aggregate of 6,396,787 shares of common stock, pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant.
February 28, 2025	The February 2025 Offering closed.

Keywords

Versamune, PDS01ADC, Infectimune, immunotherapy, clinical trials, cancer, HPV, biotechnology, pharmaceutical, FDA, NCI, Keytruda, HNSCC, vaccine, T cells

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.